Chromosome 17p Deletion and TP53 Mutation in Chronic Lymphocytic Leukemia

by Kamran Mirza MBBS PhD FCAP
April 6, 2026

If your test results mention a 17p deletion or a TP53 mutation, these findings both relate to the same gene — TP53 —, and together they represent the most clinically significant molecular finding in chronic lymphocytic leukemia (CLL). A 17p deletion removes one physical copy of the TP53 gene from the leukemia cell; a TP53 mutation damages or destroys the function of the remaining copy. Either finding alone carries major implications for treatment. When both are present together, the leukemia cell has lost all working copies of one of its most important protections against uncontrolled growth. In CLL, this combination is the clearest signal that standard chemotherapy will not work — and that targeted drugs that bypass this defect entirely are needed from the start. This article explains what these findings mean, why both tests are necessary, and how the result shapes every treatment decision throughout the course of CLL.

What the test looks for

Every cell contains two copies of the TP53 gene — one from each parent. The TP53 gene makes a protein called p53, which acts as a guardian inside cells: when a cell’s DNA is damaged, p53 steps in to either pause the cell and allow repairs or, if the damage is too severe, trigger the cell to destroy itself. This self-destruction process is one of the body’s most important defenses against cancer.

In CLL, this guardian system can be disabled in two ways, and both are tested for separately:

17p deletion. The TP53 gene sits on the short arm of chromosome 17, in a region called 17p. When a piece of this chromosome is deleted — physically lost from the cell — the copy of TP53 that lived on that piece disappears with it. One copy of the guardian gene is gone.
TP53 mutation. A mutation is a change in the gene’s code that either prevents the p53 protein from being made or produces a broken version that can no longer do its job. Even if the gene is physically present, a mutation can silence it just as effectively as deleting it.

When a CLL cell has a 17p deletion on one chromosome and a TP53 mutation on the other, both copies of the gene are disabled. The cell has no working p53 at all. This is called biallelic loss — meaning both copies have been inactivated — and it is associated with the most aggressive disease behavior and the strongest resistance to chemotherapy.

But even a single hit to TP53 — whether a deletion or a mutation alone — is clinically significant in CLL. This is because CLL cells already depend on having only one functional copy of many genes, and the loss of even one working copy of TP53 meaningfully reduces the cell’s ability to respond to DNA damage. For a fuller explanation of how p53 works as a cellular guardian, and why losing it causes chemotherapy resistance, see the related article on TP53 mutations in blood cancers.

Why are both tests necessary

Two completely different tests detect 17p deletion and TP53 mutation, and neither can find what the other looks for. Running only one of them gives an incomplete picture.

FISH detects a 17p deletion — fluorescence in situ hybridization — which uses fluorescent probes to detect whether the physical region of chromosome 17 where TP53 sits is present or absent. FISH can tell you that a copy of the gene is missing, but it cannot tell you whether the remaining copy is working. A CLL with no 17p deletion but a TP53 mutation in the remaining copy would look completely normal on FISH.

A TP53 mutation is detected by next-generation sequencing (NGS) — a technology that reads the genetic code of the TP53 gene in detail and identifies changes in the code that alter or destroy the protein’s function. Sequencing finds mutations but cannot detect deletions — a cell that has lost one entire copy of chromosome 17p will look like it still has both copies in the sequences it produces from the remaining copy.

This is why current guidelines recommend that both FISH for 17p deletion and TP53 sequencing be performed together as part of the standard CLL molecular panel. Together, they give the complete picture of TP53 status. Either test alone may miss a clinically significant finding.

Why are the tests done

In CLL, 17p deletion and TP53 mutation are tested for two reasons: to identify patients whose disease will not respond to chemotherapy-based treatment, and to guide the choice of targeted therapy that will.

Many standard CLL treatments — including fludarabine, cyclophosphamide, and chlorambucil — are chemotherapy drugs that work by damaging the DNA inside leukemia cells. They rely on the damaged cells detecting that damage and triggering their own self-destruction, a process controlled by p53. When p53 is absent or broken, the cells cannot pull this trigger. The chemotherapy damages DNA, but the leukemia cells keep dividing — meaning the treatment often fails rapidly.

Identifying a 17p deletion or TP53 mutation before treatment begins is therefore not just a prognostic exercise — it is a treatment-safety issue. Starting a patient with 17p/TP53-deficient CLL on FCR or chlorambucil-based chemotherapy exposes them to significant toxicity without meaningful benefit. The result that matters most in CLL molecular testing is knowing this before the first treatment choice is made.

Who should be tested and when

17p deletion and TP53 mutation testing are recommended for all patients with CLL at two key time points:

At diagnosis

Testing at diagnosis establishes the baseline molecular profile of the CLL. Even if the patient does not need treatment immediately — which is true for many people with newly diagnosed CLL — the result is documented as part of the overall risk assessment and will directly inform treatment decisions when treatment eventually becomes necessary.

At diagnosis, 17p deletion is found in approximately 5–8% of CLL patients, and TP53 mutations (with or without an accompanying 17p deletion) are found in approximately 10–12%. These patients are classified as high-risk and are managed differently from the outset.

Before each new treatment

This is critically important: both 17p deletion and TP53 mutation status must be retested before each new line of treatment — not just once at diagnosis.

CLL is among the cancers most prone to clonal evolution — a process in which the leukemia, under the selective pressure of treatment, gives rise to new subpopulations of cells with different mutations. 17p deletion and TP53 mutation are among the most common changes to emerge in this way. A CLL that had normal TP53 at diagnosis can acquire a 17p deletion or TP53 mutation by the time it relapses — particularly after treatment with chemoimmunotherapy, which kills cells that still have working p53 but may allow any surviving cells with TP53 mutations to expand and take over.

This means a patient who received FCR chemotherapy and responded initially, but then relapsed, may now have TP53-deficient disease even though they did not at the start. Treating relapsed CLL with another round of chemotherapy without retesting — and finding a TP53 alteration that has since emerged — is a well-recognized source of treatment failure. Current guidelines are explicit: 17p/TP53 status must be reassessed at every relapse and before every new treatment decision.

How the test is performed

Both tests are performed on a blood sample. In CLL, leukemia cells circulate in the blood in large numbers, making a simple blood draw sufficient for both FISH and sequencing — no bone marrow biopsy is needed.

FISH for 17p deletion

FISH uses small pieces of fluorescently labeled DNA designed to stick to the 17p region of chromosome 17. In a normal cell, two fluorescent signals appear — one for each copy of chromosome 17. In a cell with a 17p deletion, only one signal appears, because one copy of that region is physically absent.

The result is expressed as the percentage of cells in which the deletion is detected. In CLL, a 17p deletion is considered clinically significant when it is present in 10% or more of the cells examined. This threshold reflects that CLL is often a mixture of cells — some carrying the deletion and some not — and that a subclone present in fewer than 10% of cells is generally considered less likely to dominate the disease’s behavior, though even smaller subclones can expand over time.

NGS for TP53 mutation

Next-generation sequencing reads the genetic code of the TP53 gene in detail, checking for changes that would alter or destroy the p53 protein’s function. When a mutation is found, the report will name the specific change — for example, TP53 p.R248W — and include the variant allele frequency (VAF), which is the proportion of the cells tested that carry the mutation.

A VAF of 10% or more is generally considered clinically significant in CLL, consistent with the FISH threshold. However, even mutations with a VAF below 10% — sometimes called subclonal mutations — may be reported, and their clinical significance should be discussed with your hematologist. Small TP53-mutated subclones can expand under treatment pressure and eventually dominate the disease.

How results are reported

The FISH result will typically state the percentage of cells showing a 17p deletion, along with whether this meets the clinical significance threshold. For example: “17p deletion detected in 45% of cells examined — above the 10% threshold for clinical significance in CLL.”

The sequencing result will describe any TP53 mutations found, including the specific mutation, the type of change (missense, nonsense, frameshift), and the VAF. A combined interpretation may note whether the findings together are consistent with biallelic TP53 loss.

The report may also classify the overall findings as high-risk, particularly when both a 17p deletion and a TP53 mutation are present together.

What the result means

17p deletion detected, TP53 mutation not detected

One physical copy of TP53 is gone. The remaining copy appears intact by sequencing. This is a high-risk finding in CLL. Even with one working copy remaining, losing 50% of the cell’s p53 capacity meaningfully impairs its ability to respond to DNA-damaging chemotherapy. Standard chemotherapy-based regimens should be avoided. Targeted therapy is recommended.

TP53 mutation detected, 17p deletion not detected

One copy of TP53 carries a mutation that has silenced it — the gene is physically present, but cannot function. The other copy remains intact structurally. This is equally high-risk in CLL. The treatment implications are the same as for 17p deletion: chemotherapy is unlikely to be effective, and targeted therapy is required. This finding is precisely why sequencing is essential alongside FISH — it captures high-risk TP53 status in patients whose FISH result would otherwise look normal.

Both 17p deletion and TP53 mutation were detected.

Both copies of TP53 have been disabled — one deleted, one mutated. This is a biallelic loss, the highest-risk form of TP53 dysfunction in CLL. The leukemia cells have no working p53 at all. This finding is associated with rapid disease progression, the strongest resistance to chemotherapy, and the highest risk of Richter transformation — the conversion of CLL into a more aggressive lymphoma. Targeted therapy is essential. Clinical trial participation is strongly encouraged where available.

Neither 17p deletion nor TP53 mutation was detected.

No loss of TP53 function has been identified in the cells tested. This is a reassuring finding that opens a broader range of treatment options. It does not mean the CLL is low-risk overall — other features, such as IGHV mutation status, 11q deletion, and clinical stage, all contribute to the overall picture — but it does mean that chemotherapy-based treatment remains an option if other factors make it appropriate. TP53 status can still change over time with clonal evolution, so retesting before each future treatment decision remains important.

Treatment in 17p/TP53-deficient CLL

The treatment implications of a 17p deletion or TP53 mutation in CLL are clear and well-established. Chemotherapy-based regimens — including FCR (fludarabine, cyclophosphamide, rituximab), BR (bendamustine, rituximab), and chlorambucil — should not be used as primary treatment for this group. They are unlikely to produce meaningful remissions and expose patients to serious toxicity without proportionate benefit.

Two classes of targeted drugs work effectively in 17p/TP53-deficient CLL, both of which bypass p53 entirely — they kill or suppress CLL cells through mechanisms that do not depend on the cell detecting DNA damage and triggering its own death:

BTK inhibitors

BTK inhibitors — ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) — work by blocking a signaling protein called Bruton’s tyrosine kinase (BTK), which CLL cells rely on to receive survival signals through their B-cell receptor. Blocking BTK cuts off this signal, and the cells lose a key driver of their growth and survival. This mechanism does not require p53 — the cells are not being forced to destroy themselves through DNA damage; they are being starved of the signals they need to stay alive.

BTK inhibitors are highly effective in 17p/TP53-deficient CLL and are one of the standard first-line treatments for this group. They are taken as daily oral tablets and are typically used as continuous, long-term therapy. Responses are deep and durable in many patients, though resistance can develop over time through mutations in the BTK gene itself or downstream signaling proteins. If resistance occurs, switching to venetoclax-based therapy is the standard next step.

Venetoclax

Venetoclax (Venclyxto / Venclexta) works by blocking a protein called BCL-2, which CLL cells use to resist programmed cell death through a completely different route from the one p53 controls. BCL-2 normally acts as a brake on cell death — venetoclax releases that brake, allowing cells to die even when p53 is not working. Like BTK inhibitors, venetoclax is p53-independent.

Venetoclax is most commonly used in combination with obinutuzumab (an antibody targeting CD20 on the surface of CLL cells) as a fixed-duration regimen — typically 12 months of treatment — after which therapy is stopped. This time-limited approach is appealing to many patients. Venetoclax plus obinutuzumab is highly active in 17p/TP53-deficient CLL and is an approved first-line option for this group.

Venetoclax can also be combined with rituximab in the relapsed setting, or used as monotherapy in patients who cannot tolerate combination treatment.

Choosing between BTK inhibitors and venetoclax

Both BTK inhibitors and venetoclax were effective in 17p/TP53-deficient CLL, and were considered appropriate first-line options in current guidelines. The choice between them depends on individual factors, including your overall health, other medications you take, your preferences about continuous versus time-limited treatment, and local drug access and approval status. Your hematologist will discuss which approach is most suitable for your specific situation.

Stem cell transplantation

Before BTK inhibitors and venetoclax were available, allogeneic stem cell transplantation — using healthy blood-forming cells from a donor — was the only treatment with the potential to produce long-lasting remission in high-risk CLL. For some younger patients with multiply relapsed 17p/TP53-deficient CLL that has stopped responding to targeted therapies, transplantation may still be considered and discussed. Your hematologist will advise whether this is relevant to your situation.

What happens next

If a 17p deletion or TP53 mutation is found at diagnosis and you do not yet need treatment, your hematologist will document the result and use it to shape monitoring and future treatment planning. Watchful waiting is still appropriate for many patients with early-stage CLL, even with this high-risk finding — treatment in CLL is driven by symptoms and signs of active disease, not biomarker results alone. However, knowing the result means that when treatment is eventually needed, the right drug is chosen from the outset without delay.

If the result is found at the time treatment is first needed, your hematologist will recommend a BTK inhibitor or venetoclax-based regimen and will not offer chemotherapy-based treatment as the primary approach. The specific drug and regimen will be discussed based on your overall health, other test results, and your preferences.

If the result emerges at relapse — meaning it was not present at diagnosis but has appeared since — this is an expected pattern of clonal evolution in CLL and does not mean anything was missed in your original testing. It does mean that a treatment approach different from any chemotherapy you may have received before will now be needed. Your hematologist will explain the options.

Throughout your care, 17p/TP53 status will be retested before each new treatment decision. The result may change, and the treatment plan will be adjusted each time accordingly.

Questions to ask your doctor

Has my CLL been tested for both 17p deletion by FISH and TP53 mutation by sequencing — and if not, can both tests be arranged?
What percentage of my cells showed a 17p deletion, and do I also have a TP53 mutation?
If both are present, does that mean both copies of the TP53 gene have been disabled?
Does this result mean I should avoid chemotherapy-based treatment?
Between a BTK inhibitor and venetoclax, which treatment approach do you recommend for me, and why?
Will my 17p/TP53 status be retested before any future treatment decision, even if the result is negative now?
What signs of disease progression should I watch for, and how quickly should I contact you if they appear?
Are there clinical trials I should be aware of, given my result?